Intraventricular Conduction Delay

2

Review clinical trials related to Intraventricular Conduction Delay. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Left vs Left Randomized Clinical Trial

The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with either a wide QRS (≥130 ms) or with/anticipated \>40% pacing who are already receiving current standard heart failure pharmacological therapy.

Participants needed: 2,136
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Baylor College of MedicineUpdated: Oct 2, 2025Locations: 71
Eligibility criteria

Men and women 18 years of age or older. [+3]

Women who are pregnant, lactating, or plan to become pregnant during the course... [+13]

Status: Recruiting

UHF ECG in LBBB and Response to CRT Prediction

The main objective of the project is to demonstrate that in patients with heart failure and QRS complex of nonRBBB morphology lasting over 130 ms, UHF-ECG can differentiate patients with trueLBBB from IVCD better than existing approaches based on the assessment of QRS complex morphology and duration from 12-lead ECG. Another goal of the proposed study is to demonstrate that trueLBBB patients will benefit more from CRT using left bundle branch pacing than from CRT using biventricular pacing. The final aim of the project is to demonstrate that the echocardiographic and clinical response in patients with intraventricular conduction disturbance will be dependent on the degree of reduction in ventricular dyssynchrony after CRT.

Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Faculty Hospital Kralovske VinohradyUpdated: Jul 14, 2025Locations: 1
Eligibility criteria

HF due to ischemic or non-ischemic cardiomyopathy [+5]

Age ˂18 years [+11]